Q4 2025 Jagsonpal Pharmaceuticals Ltd Earnings Call Transcript
Key Points
- Jagsonpal Pharmaceuticals Ltd (BOM:507789) reported a strong revenue growth of 28.8% for FY25, with a significant increase in operating EBITDA by 59%.
- The company achieved a notable improvement in operating margins, reaching over 21%, and reduced working capital to 13 days or 3.5% of sales.
- Successful acquisition of Yash Pharma's Indian Bhutan business expanded therapeutic coverage and increased doctor reach by 50%.
- Cash and cash equivalents surged by 91%, providing a robust financial foundation for future growth and acquisitions.
- The company launched new products, such as Indocare P, enhancing its product portfolio and offering improved therapeutic options.
- Organic growth was below expectations, with only an 8% increase, highlighting challenges in achieving desired growth rates.
- The competitive intensity in the Dydrogestron market led to a significant decline in revenue from this franchise, impacting overall performance.
- Termination of the acquisition agreement with Resilient due to unresolved trademark issues, which could have expanded the company's portfolio.
- Q4 performance was weaker due to stockist purchasing behaviors, affecting overall quarterly results.
- High valuations in the market make it challenging to pursue brand acquisitions, limiting strategic expansion opportunities.
Ladies and gentlemen, good day and welcome to the Q4 and FY25 earnings conference call of Jagonspal Pharmaceuticals Ltd. hosted by GoIndia Advisors. (Operator Instructions) Please note that this conference is being recorded. I now hand the conference over to Ms. Formia from GoIndia Advisors. Thank you and over to you ma'am.
Good evening, everyone and welcome to the Q4 and FY25 earnings call of Jagonspal Pharmaceutical Limited. We have on call with us, representing Jagonspal, Mr. Manish Gupta, Managing Director and Mr. Sachin Jain, CFO. We must remind you that discussion on today's call may include certain forward-looking statements and must be therefore viewed in conjunction with the risks pertaining to the business. May I now request the management to take us through the financial and business outlook, subsequent to which we will open the floor to Q&A. Thank you and over to you, sir.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
